louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01311635: A Bioavailability Study Comparing 3 Different AZD1981 Tablets
Official title: A Phase I, Open Label, Randomised, 4-way Crossover Study to Investigate the Relative Bioavailability of Single Dose AZD1981 Via 3 Different Tablets in Healthy Men and Healthy Women of Non-childbearing Potential
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Phase 1
bioavailability study
AZD1981
tablets
To study the relative bioavailability of single dose AZD1981 via three different tablets
To compare the bioavailability between three different AZD1981 tablets
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-03-09
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to study the relative bioavailability of AZD1981 when using a new tablet compared to the current tablet.


Eligibility criteria: Inclusion Criteria:

* Healthy male and postmenopausal or surgically sterile female volunteers aged 18-55, inclusive
* Have a body mass index between 19-30 kg/m2 and weigh at least 50 kg and no more than 100 kg, inclusive
* Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to screening
* Volunteers must be willing to use barrier methods of contraceptive, unless their partners are post-menopausal, surgically sterile or using accepted contraceptive methods.

Exclusion Criteria:

* Any clinically significant disease or disorder
* Any clinically relevant abnormal findings in the physical examination, clinical chemistry, haematology, urinalysis, vital signs (including body temperature), or ECG assessments at Visit 1, or in vital signs (including body temperature) at Visit 2
* Prolonged QTcF \>450 ms or shortened QTcF\<340 ms at Visit 1 or family history of long QT syndrome
* History of, or current alcohol or drug abuse

Primary outcomes:
measure: Assessment of the area under the plasma concentration time-curve from zero to infinity /AUC) and the maximum plasma concentration (Cmax) of AZD1981
timeFrame: Pharmacokinetic (PK) sampling continuously for 60 h after each single dose, ie day 1-3 for each period.
Secondary outcomes:
measure: To evaluate basic systemic PK parameters as follows:
timeFrame: PK sampling continuously for 60 h after each single dose, ie day 1-3 for each period
measure: To evaluate the safety and tolerability of AZD1981 by assessment of adverse events, laboratory safety parameters, vital signs, ECG, physical examination and weight
timeFrame: Safety will be monitored continuously and safety assessments will be made on several occasions throughout the whole study
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Research Site
Study officials:
affiliation: Quintiles AB, Phase 1 Services
name: Wolfgang Kühn, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00660335: Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Official title: Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin)- Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects With a History of Acute or Acute Recurrent Pancreatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pancreatitis
Keywords: secretin, RG1068, MRCP, pancreas
Lead sponsor: Repligen Corporation
Sponsor class: INDUSTRY
First posted: 2008-04-17
Enrollment: 258
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.


Eligibility criteria: Inclusion Criteria:

* History of pancreatitis
* Medically stable
* Able to give informed consent

Exclusion Criteria:

* Prior history of pancreatic resection
* Prior history of pancreatic duct drainage procedure
* Presence of a pancreatic stent
* Unstable cardiovascular disease
* Any contraindication to MRI procedure
* Pregnancy

Primary outcomes:
measure: The primary outcome measure will be assessed by comparing baseline MRCP images and RG1068-enhanced MRCP images for the presence or absence of pancreatic abnormalities.
timeFrame: 0 - 10 minutes post dose
Secondary outcomes:
measure: The secondary outcome measure will assess safety
timeFrame: up to 30 days
Other outcomes:
Locations:
Study officials:
affiliation: Repligen Corporation
name: David R Jacoby, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Sherman S, Freeman ML, Tarnasky PR, Wilcox CM, Kulkarni A, Aisen AM, Jacoby D, Kozarek RA. Administration of secretin (RG1068) increases the sensitivity of detection of duct abnormalities by magnetic resonance cholangiopancreatography in patients with pancreatitis. Gastroenterology. 2014 Sep;147(3):646-654.e2. doi: 10.1053/j.gastro.2014.05.035. Epub 2014 Jun 4.
Clinical trial NCT06233435: Comparison of Modified Post-Anesthetic Discharge Scoring System (PADSS) Between 6 and 24 Hours in Patients Undergoing Total Knee Arthroplasty
Official title: Comparison of Modified Post-Anesthetic Discharge Scoring System (PADSS) Between 6 and 24 Hours in Patients Undergoing Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Total Knee Arthroplasty
Lead sponsor: Thammasat University Hospital
Sponsor class: OTHER
First posted: 2024-01-31
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Prospective study
Primary purpose: TREATMENT

Brief summary: This study is a prospective study which compares of Modified Post-Anesthetic Discharge Scoring System (PADSS) between 6 and 24 hours in patients undergoing total knee arthroplasty in Thammasat University hospital, Thailand.


Eligibility criteria: Inclusion Criteria:

* Patient undergoing total knee arthroplasty (one side) under spinal block with adductor canal block
* 18-85 years old
* American Society of Anesthesiologist physical status classification I-III

Exclusion Criteria:

* Allergy to local anesthetic drugs

Primary outcomes:
measure: Comparison of Modified Post-Anesthetic Discharge Scoring System (PADSS) Between 6 and 24 Hours in Patients Undergoing Total Knee Arthroplasty
timeFrame: at 6 and 24 hours after total knee arthroplasty
Secondary outcomes:
Other outcomes:
Locations:
city: Pathumthani
country: Thailand
facility: Thammasat University hospital
state: Klong Luang
Study officials:
References:
Clinical trial NCT00751335: ThermoSmart® Versus Conventional Humidification in Continuous Positive Airway Pressure (CPAP)
Official title: Prospective, Randomized, Double-blind Cross-over Study Comparing ThermoSmart® to Conventional Heated Humidity in Patients Suing Continuous Positive Airway Pressure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Apnea, Obstructive
Keywords: Obstructive Sleep Apnea
Humidification
Continuous Positive Airway Pressure
Lead sponsor: Fisher and Paykel Healthcare
Sponsor class: INDUSTRY
Collaborators: name: Suburban Lung Associates
First posted: 2008-09-11
Enrollment: 79
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: That ThermoSMart humidification will result in greater compliance (mask on time, objective and subjective sleep quality than conventional humidification.


Eligibility criteria: Inclusion Criteria:

1. ≥ 18 years of age
2. Previous diagnosis of OSA permitted, but patient must be novel to CPAP and no previous surgical intervention for OSA or treatment with an oral appliance.
3. AHI ≥ 15 OR AHI ≥ 5 + ESS ≥ 10 OR ESS ≥ 10 + a medical co-morbidity
4. Patient willing to give informed consent and follow study protocol.

Exclusion Criteria:

1. Wake resting SpO2 \< 90%
2. Patient requires BiLevel PAP or supplemental oxygen
3. The patient is medically unstable (e.g. respiratory or cardiac failure)
4. Patient unwilling to give informed consent or follow study protocol.

Primary outcomes:
measure: CPAP Compliance
timeFrame: 1, 4 & 8 weeks
Secondary outcomes:
measure: Subjective & Objective Sleep Parameters
timeFrame: 1, 4 & 8 weeks
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Suburban Lung Associates
state: Illinois
Study officials:
affiliation: Suburban Lung Asssociates
name: Clifford A Massie, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00571935: Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
Official title: Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes
Diabetes Mellitus, Type 1
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2007-12-12
Enrollment: 61
Sex: ALL
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is conducted in Europe.

The aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.


Eligibility criteria: Inclusion Criteria:

* Type 1 diabetes for at least 1 year
* HbA1c below 12.0%
* Treatment with regular human insulin and insulin NPH for at least 1 month
* Receive more than 2 injections daily

Exclusion Criteria:

* Receipt of investigational product within 6 months prior to trial participation
* Known or suspected allergy to investigational product
* Receipt of of insulin aspart within 3 months prior to trial participation

Primary outcomes:
measure: HbA1c
timeFrame: after 26 weeks of treatment
Secondary outcomes:
measure: Overall glycaemic control
measure: Occurrence of adverse events
measure: Occurrence of serious adverse events
measure: Frequency of hypoglycaemia episodes
measure: Quality of Life (QoL)
Other outcomes:
Locations:
city: Bialystok
country: Poland
facility: Novo Nordisk Investigational Site
city: Gliwice
country: Poland
facility: Novo Nordisk Investigational Site
city: Kielce
country: Poland
facility: Novo Nordisk Investigational Site
city: Krakow
country: Poland
facility: Novo Nordisk Investigational Site
city: Warszawa
country: Poland
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Pankowska E, Nazim J, Szalecki M, Urban M. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children. Diabetes Technol Ther. 2010 May;12(5):413-8. doi: 10.1089/dia.2009.0155.
Clinical trial NCT03861858: Dialectical Behavior Therapy for Adolescents at Rutgers University
Official title: Dialectical Behavior Therapy for Adolescents at Rutgers University
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Borderline Personality Disorder in Adolescence
Keywords: borderline personality disorder
adolescence
suicide
substance use
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
First posted: 2019-03-04
Enrollment: 56
Sex: ALL
Minimum age (years): 13
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This project expands our existing psychological services clinic (the Dialectical Behavior Therapy Clinic at Rutgers University; DBT-RU) to include an adolescent treatment arm. Adolescents aged 13-20 and at least one caregiver will be recruited to participate in a six-month treatment study. Adolescents will be eligible to participate if they meet at least 3 criteria for borderline personality disorder, with one of those criteria being either impulsive behavior or recurrent self-harm behavior. Participants will be assessed at baseline, three-months (mid-treatment), six-months (post-treatment, and three-month follow-up.


Eligibility criteria: Inclusion Criteria:

* Age 13-17 years or 18-20 if still living at home with parent.
* Agreement of at least one responsible adult parent/caregiver to participate in treatment.
* Agreement to take part in assessments, videotaping/audiotaping and coding of their sessions by research personnel.
* Agreement to pay for mental health services at the DBT- RU on a sliding scale, and to participate in research assessments as volunteers.
* Residence within commuting distance of clinic (\< 45 minutes).
* Agreement to discontinue other forms of talk therapy for duration of DBT program (does not refer to AA/NA programs or psychotropic medication management).
* Exhibits dysregulation within the past six months as evidenced by 1) intentional self-injury and/or suicide attempt and/or 2) substance use disorder.
* Meets two additional criteria for borderline personality disorder (BPD).

Exclusion Criteria:

* Clients who need mental health services not available at the DBT- RU, such as treatment for schizophrenia or life-threatening anorexia, or who are currently obtaining optimum professional treatment that should not be ended.
* Non-English speaking.
* IQ \< 70.
* Unable to understand research consent forms.
* Court-ordered to participate in treatment.

Primary outcomes:
measure: Self-Injurious Thoughts and Behaviors Inventory (SITBI)
timeFrame: six months
measure: Work and Social Adjustment Scale
timeFrame: six months
Secondary outcomes:
measure: Difficulties in Emotion Regulation Scale (DERS)
timeFrame: six months
measure: Borderline Symptom List (BSL-23)
timeFrame: six months
measure: Brief Symptom Inventory (BSI)
timeFrame: six months
Other outcomes:
Locations:
city: Piscataway
country: United States
facility: Rutgers University
state: New Jersey
Study officials:
References:
Clinical trial NCT02860858: Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
Official title: Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Symtomatic Macular Polypoidal Choroidal Vasculopathy
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
First posted: 2016-08-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Objective: To evaluate the efficacy of intravitreal aflibercept injection on visual acuity in patients with symptomatic macular PCV.


Eligibility criteria: Inclusion Criteria:

* Male or Female \>/= 18 years
* Confirmed diagnosis of symptomatic macular PCV in the study eye defined by: - Active macular polypoidal lesions shown by ICGA and - Presence of serosanguinous maculopathy
* BCVA letter score between 78-24 using ETDRS visual acuity chart measured at 4 meters

Exclusion Criteria:

* Previous treatment with systemic anti-VEGF drugs within 6 months prior to Baseline (e.g., sorafenib \[Nexavar®\], sunitinib \[Sutent®\], bevacizumab \[Avastin®\])

Study eye:

* Active ocular inflammation or infection (ocular or periocular)
* Uncontrolled intraocular hypertension or glaucoma (IOP\> 30 mmPIg) despite treatment with anti-glaucoma medication
* Predominantly-scarred PCV lesions
* Ocular disorders in the study eye (e.g. cataract, retinal vascular occlusion, diabetic retinopathy) that, in the opinion of the investigator may confound interpretation of study results or compromise VA or require medical or surgical intervention during the study period
* Prior treatment with verteporfin PDT, external-beam radiation, subfoveal or extrafoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy
* Prior treatment with any anti-VEGF compound or any investigational treatment
* Treatment with intravitreal or subtenon corticosteroid injection or device implantation within 90 days

Primary outcomes:
measure: Best corrected visual acuity (BCVA)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
Study officials:
References:
Clinical trial NCT05330858: Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
Official title: The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Lead sponsor: Alumis Inc
Sponsor class: INDUSTRY
First posted: 2022-04-15
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This is a single-center, in-house, open-label, crossover study in 15 healthy participants.

Detailed description: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Eligibility criteria: Inclusion Criteria:

* Healthy Men and woman age 18-60
* Able to provide written informed consent
* Females can not be pregnant or lactating

Exclusion Criteria:

* Prior exposure to ESK-001
* History of malignancy within the last 10 years
* Positive for HIV, Hepatitis B or C
* History of tuberculosis
* Positive test for alcohol or drugs

Primary outcomes:
measure: Assess the PK parameters of ESK-001 via time of maximum plasma concentration (Tmax)
timeFrame: 18 Days
measure: Assess the PK parameters of ESK-001 via maximum plasma concentration (Cmax)
timeFrame: 18 Days
measure: Assess the PK parameters of ESK-001 via area under the concentration time curve (AUC)
timeFrame: 18 Days
Secondary outcomes:
measure: Assess the Incidence of Treatment Emergent Adverse Events of ESK-001
timeFrame: 25 Days
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Alumis Central Site
state: California
Study officials:
References:
Clinical trial NCT05904158: Effects of Platelet-Rich Fibrin in Patients With Anterior Cruciate Ligament Reconstruction
Official title: Effects of Platelet-Rich Fibrin on Knee Muscle Strength and Function in Patients With Anterior Cruciate Ligament Reconstruction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Effects of Platelet-Rich Fibrin on Knee Stability and Knee Function
Keywords: Anterior cruciate ligament
platelet-rich fibrin
return to play
Lead sponsor: Hacettepe University
Sponsor class: OTHER
Collaborators: name: Ankara City Hospital Bilkent
First posted: 2023-06-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomised controlled design
Primary purpose: TREATMENT

Brief summary: The study was conducted to investigate the effects of platelet-rich fibrin on knee stability, knee muscle strength and knee function in patients with ACL reconstruction. Thirty patients with ACL reconstruction were included to the study and randomly divided into two groups. Patients were assessed preoperative and at the postoperative 1-year.

Detailed description: The study was conducted yo investigate the effects of platelet-rich fibrin (PRF) on the knee stability and function in patients with anterior cruciate ligament (ACL) reconstruction. Thirty patients with ACL reconstruction were included to the study and randomly divided into two groups (PRF group and control group). Hamstring tendon autograft was used in all patients for the reconstruction of the teared ACL. A standardized postoperative rehabilitation program was applied to all patients. Patients' knee stability, knee muscle strength and knee function were assessed preoperatively and one-year postoperatively. Knee stability was assessed using KT-2000 Knee Arthrometer. Quadriceps femoris and hamstring muscle strength measurements were conducted with an isokinetic dynamometer at 60˚/sec and 180˚/sec angular velocities. One Leg Hop (OLH) and Y-Balance tests, and International Knee Documentation Committee (IKDC) were used to evaluate the knee function.

Eligibility criteria: Inclusion Criteria:

* Being isolated ACL reconstruction,
* Being between the ages of 18-45 years,
* Performing sports recreationally or professionally

Exclusion Criteria:

* Having previous knee surgery,
* Having systematic disease,
* Having multiple ligament injury on the knee or additional cartilage injuries

Primary outcomes:
measure: Changes in the Knee Laxity
timeFrame: Preoperatively ans one year postoperatively
Secondary outcomes:
measure: Changes in the Knee Muscle Strenght
timeFrame: Preoperatively ans one year postoperatively
measure: Changes in the Knee Function
timeFrame: Preoperatively and one year postoperatively
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04912258: Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver Metastasis
Official title: Trans-arterial Chemoembolization With Irinotecan Drug-eluting Beads Before Liver Surgery for Patients With Primary Unresectable Colorectal Liver Metastasis: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Colorectal Cancer
Liver Metastases
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2021-06-03
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Trans arterial chemoembolization using Irinotecan Drug-eluting Beads before liver surgery for patients with primarily unresectable colorectal liver metastasis


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years;
* Histologically proven colorectal liver metastasis；
* With liver-dominant disease；
* Primarily evaluated as potentially resectable and conversed successfully
* Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 (within 1 week prior to randomization)
* Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl (within 1 week prior to randomization);
* Written informed consent for participation in the trial.

Exclusion Criteria:

* Primarily evaluated as resectable
* Failed to converse
* Patients with known hypersensitivity reactions to any of the components of the study treatments.
* Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding
* Other previous malignancy within 5 years
* Known drug abuse/ alcohol abuse
* Legal incapacity or limited legal capacity

Primary outcomes:
measure: liver relapse-free survival
timeFrame: 6 months
Secondary outcomes:
measure: relapse-free survival
timeFrame: 6 months
measure: overall survival
timeFrame: 12 months
measure: response rate
timeFrame: 2 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Zhongshan Hospital Fudan University
state: Shanghai
Study officials:
References: